Étiquette : safety

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study, Carla M. Canuso et al., 2018,

Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study Carla M. Canuso, M.D., Jaskaran B. Singh, M.D., Maggie Fedgchin, Pharm.D., Larry Alphs, M.D., Ph.D., Rosanne Lane, M.A.S., Pilar Lim, Ph.D., Christine Pinter, M.S., David Hough, M.D., Gerard Sanacora, M.D., Ph.D., Husseini Manji, M.D., Wayne C. Drevets, M.D. American Journal of Psychiatry, 2018, 175, 620–630 doi: 10.1176/appi.ajp.2018.17060720   Objective : The authors compared the efficacy of standardof- care treatment plus intranasal esketamine or placebo for rapid reduction of symptoms of major depression, including suicidality, among [...]

Lire la suite

Psychedelic Drugs in Biomedicine, Evan J. KYZAR, 2017

Psychedelic Drugs in Biomedicine Evan J. KYZAR, Charles D. NICHOLS, Paul R. GAINETDINOV, David E. NICHOLS, Allan V. KALUEFF  Trends in Pharmacological Sciences, 2017, 38, (1), 992-1005 https://doi.org/10.1016/j.tips.2017.08.003 Trends Psychedelic drugs profoundly alter human behavior, acting primarily via agonism at the 5-HT2A receptor in the brain. Research into the mechanisms of psychedelic drugs is experiencing a renaissance after years of stagnation. Animal models show that psychedelic drugs alter a number of crucial molecular mechanisms. Psychedelic drugs cause widespread changes in cognition and brain connectivity. Recent pilot studies show LSD and psilocybin are effective in treating psychiatric disorders and possibly other illnesses. Psychedelic biomedicine is rapidly emerging as an important area [...]

Lire la suite

Potential Therapeutic Effects of Psilocybin, Matthew W. Johnson & Roland R. Griffiths, 2017

Potential Therapeutic Effects of Psilocybin Matthew W. Johnson & Roland R. Griffiths Neurotherapeutics, 2017, 14, 734–740 DOI 10.1007/s13311-017-0542-y Abstract Psilocybin and other 5-hydroxytryptamine2A agonist classic psychedelics have been used for centuries as sacraments within indigenous cultures. In the mid-twentieth century they were a focus within psychiatry as both probes of brain function and experimental therapeutics. By the late 1960s and early 1970s these scientific inquires fell out of favor because classic psychedelics were being used outside of medical research and in association with the emerging counter culture. However, in the twenty-first century, scientific interest in classic psychedelics has returned and grown as a result of [...]

Lire la suite

Long-term effects of ayahuasca in patients with recurrent depression : a 5-year qualitative follow-up, Rafael G. dos Santos et al., 2018,

Long-term effects of ayahuasca in patients with recurrent depression : a 5-year qualitative follow-up Rafael G. dos Santos, Rafael Faria Sanches, Flávia de Lima Osório, Jaime E.C. Hallak Archive of Clinical Psychiatry, 2018, 45, 1, 22-4 DOI: 10.1590/0101-60830000000149 Abstract Background : Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for [...]

Lire la suite

Psychedelics Promote Structural and Functional Neural Plasticity, Astral X Neural Plasticity, Alexandra C. Greb et al., 2018

Psychedelics Promote Structural and Functional Neural Plasticity Astral X Neural Plasticity, Alexandra C. Greb, Lindsay P. Cameron, Jonathan M. Wong, Eden V. Barragan, Paige C. Wilson, Kyle F. Burbach, Sina Soltanzadeh Zarandi, Alexander Sood, Michael R. Padd, Whitney C. Duim, Megan Y. Dennis, A. Kimberley McAllister, Kassandra M. Ori-McKenney, John A. Gray and David E. Olson Experiment Findings, February 2018 https://www.researchgate.net/publication/331396378   SUMMARY Atrophy of neurons in the prefrontal cortex (PFC) plays a key role in the pathophysiology of depression and related disorders. The ability to promote both structural and functional plasticity in the PFC has been hypothesized to underlie the fast-acting antidepressant properties of the [...]

Lire la suite

Study will test pot’s effects on infants’ brain development, Brian Donohue, UW Medicine School of Medecine, 2019

May 10, 2019 Study will test pot’s effects on infants’ brain development Researchers seek to isolate cannabis from concurrent use of alcohol, tobacco, and illicit drugs. Media Contact: Brian Donohue - 206.543.7856, bdonohue@uw.edu Kleinhans Lab MRI scans of infants’ brains are part of the evaluation to discern effects of prenatal marijuana exposure. UW Medicine researchers are recruiting pregnant women to study whether prenatal marijuana use – in the absence of alcohol, tobacco, and any illicit drug consumption – affects their infants’ brain development, cognitive and motor development, medical health, and social behavior. The “Moms + Marijuana” study is co-led by Drs. Natalia Kleinhans and Stephen Dager, radiologists at [...]

Lire la suite

Cannabis Companies Push F.D.A. to Ease Rules on CBD Products, Sheila Kaplan, The New York Time, May 31, 2019

Cannabis Companies Push F.D.A. to Ease Rules on CBD Products By Sheila Kaplan The New York Time, May 31, 2019 CBD products have exploded in recent years, and are so numerous and varied as to include cheese pizza and fruit smoothies, like at this restaurant in Fort Lauderdale, Fla.CreditJennifer Lett/South Florida Sun-Sentinel, via Associated Press Image CBD products have exploded in recent years, and are so numerous and varied as to include cheese pizza and fruit smoothies, like at this restaurant in Fort Lauderdale, Fla.CreditCreditJennifer Lett/South Florida Sun-Sentinel, via Associated Press     WASHINGTON — It was Hempy Pet CBD Soft Chews, Mile High Labs and Women Grow, [...]

Lire la suite

Cannabidiol in Anxiety and Sleep : A Large Case Series, Scott Shannon et al., 2019

Cannabidiol in Anxiety and Sleep : A Large Case Series Scott Shannon, Nicole Lewis, Heather Lee,  Shannon Hughes, The Permanente Journal, 2019, 23, 18-041 doi.org/10.7812/TPP/18-041   ABSTRACT Context : Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. It does not appear to alter consciousness or trigger a “high.” A recent surge in scientific publications has found preclinical and clinical evidence documenting value for CBD in some neuropsychiatric disorders, including epilepsy, anxiety, and schizophrenia. Evidence points toward a calming effect for CBD in the central nervous system. Interest in CBD as a treatment of a wide range of disorders has exploded, yet few clinical [...]

Lire la suite

Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy, James W. Wheless et al., 2019

Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol in Pediatric Patients with Treatment-Resistant Epilepsy James W. Wheless, · Dennis Dlugos, · Ian Miller, · D. Alexander Oh, · Neha Parikh, · Steven Phillips, · J. Ben Renfroe, · Colin M. Roberts, · Isra Saeed, · Steven P. Sparagana, · Jin Yu, · Maria Roberta Cilio, on behalf of the INS011-14-029 Study Investigators CNS Drugs, 2019 https://doi.org/10.1007/s40263-019-00624-4 Abstract Background : Prior studies have evaluated the use of various constituents of cannabis for their anti-seizure effects. Specifically, cannabidiol, a non-psychoactive component of cannabis, has been investigated for treatment-resistant epilepsy, but more information is needed particularly on [...]

Lire la suite

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition, T.R. Arkell et al., 2019

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Arkell T.R., Lintzeris N., Kevin R.C., Ramaekers J.G., Vandrey R., Irwin C., Haber P.S., McGregor I.S. Psychopharmacology (Berlin), 2019 DOI : 10.1007/s00213-019-05246-8 PMID : 31044290 Abstract BACKGROUND : The main psychoactive component of cannabis, delta-9-tetrahydrocannabinol (THC), can impair driving performance. Cannabidiol (CBD), a non-intoxicating cannabis component, is thought to mitigate certain adverse effects of THC. It is possible then that cannabis containing equivalent CBD and THC will differentially affect driving and cognition relative to THC-dominant cannabis. AIMS : The present study investigated and compared the effects of THC-dominant and [...]

Lire la suite